Prognostic factors in aggressive lymphoma: the contribution of novel biological markers.
Montserrat
E
E
Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras-Valentí, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Spain. emili@medicina.ub.es
D014408:Biomarkers, Tumor / Q000097:blood*; D002869:Chromosome Aberrations; D020869:Gene Expression Profiling; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000235:genetics; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000401:mortality*; D009363:Neoplasm Proteins / Q000097:blood; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D012720:Severity of Illness Index; D014178:Translocation, Genetic
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; C107023:p80(NPM-ALK) protein; D011505:Protein-Tyrosine Kinases